Advertise on podcast: Meeting Mic

In this episode of Meeting Mic, we bring you pearls and perspectives from the American Society of Retina Specialists Annual Meeting. In an interview, Anat Loewenstein, MD, MHA, of Tel Aviv Medical Center, talks about how Home OCT combined with an AI analysis helped in the early detection of retinal fluid in patients with age-related macular degeneration. Next, David Almeida, MD, MBA, PhD, of Erie Retina Research in Pennsylvania, talks about how CG-P5, a topical peptide eye drop, met safety and efficacy endpoints for wet age-related macular degeneration. Hasenin Al-khersan, MD, discusses findings from a retrospective study on pegcetacoplan slowing photoreceptor and retinal pigment epithelium loss in patients with geographic atrophy only as well as patients with GA and concurrent wet age-related macular degeneration. Sunir J. Garg, MD, FACS, FASRS, discusses findings from a real-world study about suprachoroidal triamcinolone acetonide having a durable effect in patients with chronic cystoid macular edema. And, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston tells us about her study on systemic statin use reducing the rate of proliferative vitreoretinopathy and reoperation following primary retinal detachment repair by nearly half. Read the full coverage here: Home OCT with AI comparable to expert graders in AMD Loewenstein A. Longitudinal performance of a trend analysis algorithm for home OCT monitoring in neovascular age-related macular degeneration (NVAMD). Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal. Peptide eye drop shows fluid, thickness reductions in patients with wet AMD Almeida D, et al. Efficacy and safety of a novel topical peptide (CG-P5) for the treatment of neovascular age-related macular degeneration: Phase 1 results. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montréal, Canada Pegcetacoplan slows photoreceptor, RPE loss in patients with GA and concurrent wet AMD Al-khersan H. Assessment of geographic atrophy progression following pegcetacoplan in the real world with and without neovascular age-related macular degeneration. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal. Suprachoroidal triamcinolone shows durable effect in cystoid macular edema Garg SJ, et al. Durability and safety of suprachoroidal triamcinolone acetonide in eyes with chronic cystoid macular edema in real-world clinical practice. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal. Study: Statin use halves risk for PVR after retinal detachment surgery Weng CY, et al. Statin use and association with proliferative vitreoretinopathy and reoperation risk following retinal detachment surgery. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal. Al-khersan reports consulting for Apellis. Almeida reports being a researcher and consultant for Caregen. Garg reports consulting for Bausch + Lomb. The study was funded by Bausch + Lomb. Loewenstein reports consulting for Notal Vision. Weng reports no relevant financial disclosures.

In this episode of Meeting Mic, Oncology Overdrive host, Shikha Jain, MD, is joined by Akriti Jain, MD, to discuss innovations in the management of acute myeloid leukemia, as well as highlights and abstracts from ASCO Annual Meeting. ·       What advances have you seen in AML care over the past 10 to 12 years? 5:57 ·       How do you manage treatment of patients with TP53-mutated AML? 13:39 ·       What types of disparities do you see in your patient populations? 15:48 ·       What advice do you give patients to help them better understand the benefits of clinical trials? 20:51 ·       What abstracts were you most excited about at ASCO this year? 25:18 ·       Is personalized care becoming more of a focus in AML management? 27:19 We'd love to hear from you! For more from Dr. Shikha Jain, follow her on X: @ShikhaJainMD and on Instagram: @shikhajainmd. For more from Dr. Akriti Jain, email [email protected]. Shikha Jain reports no relevant financial disclosures. Akriti Jain reports advising/consulting roles with Ascentage Pharma, Daiichi Sankyo, Novartis, Servier, Sobi, Syndax and Takeda, and research funding from Novartis and Servier. She also has served as a speaker for Geron, PharmaEssentia and Rigel Pharmaceuticals. References: ·        Granat LM, et al. Abstract 6587. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. ·        Pino-Ascencio S, et al. Abstract 6580. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

In this episode of Meeting Mic, we bring you pearls and perspectives in breast cancer from ASCO Annual Meeting. In an interview, Jame Abraham, MD, discusses the DESTINY-Breast05 study, as well as clinical and demographic risk factors for interstitial lung disease and radiation pneumonitis. Next, Shimoli Barot, MD, discusses results from the phase 3 lidERA BC clinical trial of premenopausal vs. postmenopausal women with breast cancer. Sara A. Hurvitz, MD, FACP, provides an overview of the ASCENT-03 study of a subset of women with triple-negative breast cancer. And, Sherry Shen, MD, talks about a presentation on mutational signatures and related outcomes in metastatic invasive lobular carcinoma. Read the full coverage here: VIDEO: Clinicians 'should continue to pay attention' to T-DXd side effects in breast cancer Untch M, et al. Abstract 516. Presented at: ASCO Annual Meeting; May 29-June 2, 2016; Chicago. VIDEO: Giredestrant improves breast cancer survival, regardless of menopause status Healio Interviews VIDEO: Sacituzumab govitecan delays subsequent therapy in breast cancer subset Hurvitz SA. Abstract 1001. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. VIDEO: Survival in metastatic invasive lobular carcinoma differs by mutational signature Shen S, et al. Abstract 1141. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. 'Reassuring': Omitting full axillary dissection does not worsen survival in breast cancer De Boniface J, et al. Abstract LBA503. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. Abraham reports research funding from AstraZeneca/Daiichi Sankyo and Pfizer. Barot and Shen report no relevant financial disclosures. Hurvitz reports research funding from AstraZeneca/Daiichi Sankyo, Novartis and Stemline Therapeutics; and advisory or consulting roles with Akari Therapeutics, ALX Oncology, Bayer, BeOne Medicines, Blueprint Medicines, Boundless Bio, BriaCell, BridgeBio Pharma, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly Oncology, Ellipses Pharma, EMBioSys, Gilead Sciences, Jazz Pharmaceuticals, Luminate Medical, Mersana Therapeutics, Myricx Bio, Prelude Therapeutics and Roche.

In this episode of Meeting Mic, we bring you pearls and perspectives in metastatic breast cancer from the American Society of Clinical Oncology 2026. In an interview, Shimoli Barot, MD, discusses a genomic test which could be used to identify patients with ER-positive, HER2-negative breast cancer who may be able to avoid chemotherapy. Next, Erika P. Hamilton, MD, discusses the HER2-CLIMB05 trial for patients with HER2-positive metastatic breast cancer. And, Sherry Shen, MD, discusses lifestyle and survivorship for patients with breast cancer, specifically with GLP-1 use. Read the full coverage here: VIDEO: Genetic test helps identify patients with breast cancer who may avoid chemotherapy Source: Healio Interviews VIDEO: Tucatinib plus trastuzumab, pertuzumab safe for HER2-positive breast cancer Source: Hamilton EP. Abstract 1005. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. VIDEO: Less weight loss, improved survival for GLP-1 use in women with breast cancer Source: Shen S. Optimizing breast cancer survivorship: Addressing lifestyle, weight management, and psychological health. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. 'Critically important': Upfront sacituzumab govitecan combo benefits breast cancer subset Source: Kalinsky K, et al. Abstract LBA1000. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. 'Real value': Remote program significantly improves physical function in breast cancer Source: Ligibel JA, et al. Abstract 12010. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. Barot and Shen report no relevant financial disclosures. Hamilton reports receiving research funding from Abbvie, Accutar Biotechnology, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, BeOne Medicines, Bicycle Therapeutics, Biohaven Pharmaceuticals, BioNTech, Compugen, Cullinan, Daiichi Sankyo, Dantari, Day One Biopharmaceuticals, Duality Biologics, Ellipses Pharma, Elucida Oncology, Exelixis, FujiFilm, Genmab, Gilead Sciences, H3 Biomedicine, Iambic Therapeutics, Immunogen, Inspirna, InventisBio, Jacobio, Jazz Pharmaceuticals, K-Group Beta, Kind Pharmaceuticals, Lilly, Loxo Oncology, Mabspace Biosciences, Mabwell Bioscience, Marengo Therapeutics, MediLink Therapeutics, Merck, Mersana, Novartis, Olema, Orinove, Orum Therapeutics, Pfizer, Pionyr Immunotherapeutics, Prelude Therapeutics, Profound Bio, Regeneron, Relay Therapeutics, Rgenix, Roche/Genentech, SeaGen, Shattuck Labs, Simcha Therapeutics, Stemline Therapeutics, Sutro, Systimmune, Taiho, Tesaro, TheRas, Treadwell Therapeutics, Verastem, Xadcera Biopharmaceutical and Zymeworks; and consulted or advised for ADC Therapeutics, Arvinas, AstraZeneca, BeOne Medicines, BicycleTx, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol-Myers Squibb, Daiichi Sankyo, Gilead Sciences, Halda Therapeutics, Hexagon Bio, Immunome, Incyclix Bio, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mersana Therapeutics, Novartis, Pfizer, Precede Biosciences, Pyxis Oncology, Rigel Pharmaceuticals, Roche/Genentech, Samsung Bioepis, Shorla Pharma and Stemline Therapeutics.

In this episode of Meeting Mic, Mark Leiser, Healio's Oncology Insider, joins Shikha Jain, MD, to discuss top presentations, as well as pearls and perspectives from ASCO Annual Meeting. ·       Daraxonrasib offers 'transformational' benefit in metastatic pancreatic cancer ·       GLP-1s demonstrate 'large' & 'consistent' protective effects against cancer metastases ·       Trial of early cancer detection test misses primary endpoint; secondary data 'promising' ·       'This matters': Hem/onc fellows embrace AI but lack formal training to guide its use ·       Hem/onc 'bootcamp' significantly improves fellows' knowledge, clinical confidence ·       Immunotherapy combination may improve outcomes in unresectable liver cancer ·       Abemaciclib may be new standard for 'challenging' sarcoma subtype For more of the latest breaking news in oncology, be sure to visit Oncology Insider. We'd love to hear from you! For more from Dr. Jain, follow her on X: @ShikhaJainMD and on Instagram: @shikhajainmd. For more from Leiser, follow him on X: @_MarkLeiser or on LinkedIn. Jain and Leiser report no relevant financial disclosures.

In this episode of Meeting Mic, we bring you pearls and perspectives from the Association of Vision and Research in Ophthalmology 2026. Jason Greenfield, MD, MBA, Alon Harris, MS, PhD, FARVO, and Yash Lahoti spoke with Healio about their study, which was designed to look at some of the unknown risk factors for glaucoma. 00:37 Next, Michael Zhu, a medical student at Duke University School of Medicine, told Healio about his presentation about retina imaging and how it may reveal links to Parkinson's disease. 06:12 And, Iris Fang-Yu Hu, MD, discusses her presentation on how using visual prompts helped improve glaucoma detection by a large language model. 08:35 Top headlines from the meetings. 09:31 Read the full coverage here: Glaucoma, hypertension may be linked to dementia risk Source: Greenfield J, et al. Artificial intelligence ready and exploratory atlas for diabetes insights: The association between glaucoma, hypertension, and cognitive performance. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver. Imaging reveals link between inner nuclear layer thickness, Parkinson's disease Source: Zhu M, et al. Macular retinal layer thickness in early Parkinson's disease. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver. Reference images help AI model detect glaucoma Source: Hu I, et al. Providing reference images to LLMs improves glaucoma detection from fundus photos. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver. Smoking may be modifiable risk factor for myopia-related vision loss Source: Flitcroft I, et al. Smoke gets in your eyes: Evidence that smoking is the first modifiable risk factor for myopia-related vision impairment. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver. Thyroid eye disease shows long-term progression in real-world dataset Source: Ramesh S, et al. Disease progression in thyroid eye disease: Findings from a large real-world study in the United States. Presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2026; Denver.

In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Neurology (AAN) Annual Meeting 2026. Christopher Lock, MD, discusses key takeaways from the meeting. 00:12 Claire Delpirou Nouh, MD, highlights the meeting's major discussions and presentations. 05:27 Top headlines from the meetings. 08:42 Read the full coverage here: Improved mortality outweighs cognitive risks in GLP-1 analog use Source: Thorman IB, et al. Long-term risk of cognitive impairment with GLP-1 analogues in older adults with type 2 diabetes mellitus. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Prolonged seizures negatively impact productivity, quality of life in patients, caregivers Source: Trinka E, et al. Loss of productivity, seizure worry, and patient and caregiver quality of life associated with prolonged seizures: Results from a global real-world point-in-time study. Presented at: American Academy of Neurology Annual Meeting; April 18-22, 2026; Chicago. Improvements in biological age linked to lower stroke risk, healthier brains Source: Rivier C, et al. Improvements in biological age acceleration lead to better neuroimaging, clinical and cognitive markers of brain health. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

In this episode of Meeting Mic, we bring you pearls and perspectives from Miami Breast Cancer Conference 2026. Paolo Tarantino, MD, PhD, discusses key takeaways from the meeting. :19 Paolo Tarantino, MD, PhD, highlights the meeting's major discussions and presentations. 3:02 Hope S. Rugo, MD, provides an overview of the inspiring and revelatory information presented at the conference. 4:41 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20260317/video-oncology-education-key-to-understanding-growing-data-in-breast-cancer-treatment https://www.healio.com/news/hematology-oncology/20260317/video-discussions-on-her2positive-breast-cancer-treatment-may-alter-way-of-practicing  https://www.healio.com/news/hematology-oncology/20260317/video-trastuzumab-deruxtecan-in-adjuvant-setting-may-be-preferred-in-breast-cancer https://www.healio.com/news/hematology-oncology/20260325/video-breast-cancer-conference-fuses-data-specialties-in-continuum-of-patient-care https://www.healio.com/news/hematology-oncology/20260325/video-keynote-speaker-inspires-others-to-push-beyond-the-barriers-in-breast-cancer

In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2025, as well as Healio's top headlines from the meeting. Amy Comander, MD, DipABLM, FACLM, MSCP, highlights presentations at this year's meeting. :26 Jun J. Mao, MD, MSCE, discusses results from a phase 2 trial surrounding acupuncture for breast cancer. 1:50 Amanda M. Woodworth, MD, FACS, CPE, describes a digital toolkit for advancing risk-informed breast cancer screening. 4:41 Read the full coverage here: Advancements in Breast Cancer, Lifestyle Medicine and A Preview of SABCS with Amy Comander, MD Sentinel node biopsy pioneer to receive William L. McGuire Memorial Lecture Award Tucatinib regimen delays disease progression in advanced HER2-positive breast cancer Disclosures: Comander reports no relevant financial disclosures. Healio could not confirm financial disclosures for Mao and Woodworth at the time of publishing.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 Neuroscience Educational Institute (NEI) Annual Congress. David W. Goodman, MD, LFAPA, discusses his presentation about ADHD in adults including diagnosis, treatment and the current challenges. :22 Katherine Dahlsgaard, PhD, ABPP, talks about her presentations on behavioral interventions for sleepy adolescents as well as the challenges physicians face in prescribing psychiatric medicines. 5:43 Kari L. Franson, PharmD, PhD, BCPP, FNAP, highlights her presentations on the current status of prescription digital therapeutics and the practice of de-prescribing psychiatric medicines.  17:28 Disclosures: Goodman reports receiving honoraria from Clinical Care Options, HCPLive, Medscape, Neuroscience Education Institute and World Federation for ADHD. Healio was unable to confirm relevant disclosures for Dahlsgaard or Franson at the time of publication.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 Gerontological Advanced Practice Nurses Association (GAPNA) Annual Conference. Kimberly Posey, AGPCNP-BC, DNP, PhD, GS-C, discusses the purpose for the meeting, and highlights from this year's conference. :19 George Peraza-Smith, DNP, A-GNP-C, GNP-BC, GS-C, CNE, FAANP, immediate past president of GAPNA, provides an overview on popular presentations from the meeting, and goals for the future of the organization. 12:25 Disclosures: Healio was unable to confirm relevant disclosures at the time of publication.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Society of Retina Specialists annual meeting, as well as Healio's top headlines from the meeting. Andrew G. Lee, MD, discusses when retina experts should refer patients to a neuro-ophthalmologist. 0:29 Sunir J. Garg, MD, FACS, FASRS, provides an overview of lessons learned from two complex surgical cases. 1:52 Sunir J. Garg, MD, FACS, FASRS, overviewed key findings from the Global Trends in Retina Survey. 5:16 Michael O'Rouke talks collaborating with Boehringer Ingelheim to develop extended-release therapies for ophthalmic diseases. 8:17 Jay S. Duker, MD, discusses EyePoint Pharmaceuticals' second phase 3 trial of Duravyu in patients with wet age-related macular degeneration. 11:08 Read the full coverage here: https://www.healio.com/news/ophthalmology/20250731/andrew-g-lee-shares-neuroophthalmology-advice-for-retina-specialists https://www.healio.com/news/ophthalmology/20250731/sunir-garg-shares-solutions-to-complex-surgical-cases https://www.healio.com/news/ophthalmology/20250730/revana-collaborates-with-boehringer-ingelheim-to-develop-extendedrelease-therapies https://www.healio.com/news/ophthalmology/20250807/eyepoint-completes-enrollment-in-second-phase-3-trial-of-sustainedrelease-amd-therapy https://www.healio.com/news/ophthalmology/20250811/survey-treatment-for-recalcitrant-diabetic-macular-edema-varies-between-us-europe Long-term benefits seen with Gore-Tex sutures for scleral fixation of IOLs Source: Acaba-Berrocal L, et al. Long-term outcomes of pars plana vitrectomy and polytetrafluoroethylene sutured scleral-fixated intraocular lenses. Presented at: American Society of Retina Specialists annual meeting; July 30-Aug. 2, 2025; Long Beach, California. Study supports Iluvien as 'long-acting option' in diabetic macular edema Source: Singer MA, et al. NEW DAY: Study design, study sites, patient enrollment: A study of intravitreal Iluvien (fluocinolone acetonide) implant as baseline therapy in patients with early diabetic macular edema (DME) (NEW DAY). Presented at: American Society of Retina Specialists annual meeting; July 30-Aug. 2, 2025; Long Beach, California. Disclosures: Duker reports being president and CEO of EyePoint Pharmaceuticals. Garg reports no relevant financial disclosures. Lee reports no relevant financial disclosures. O'Rourke reports being CEO of Re-Vana Therapeutics.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Chinmay Jani, MD, discusses findings highlighting how alcohol-related cancer mortality has risen sharply over the past few decades. :19 Rachel I. Vogel, PhD, provides and overview on factors contributing to the time burden cancer care places on patients. 3:02 Alexander D. Sherry, MD, discusses how improvements in OS or quality of life after phase 3 oncology trials are based on improvements in unvalidated alternative endpoints. 4:41 Lucas A. Mavromatis, ScB, discusses findings on how GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes. 7:20 Sonali M. Smith, MD, talks with Oncology Overdrive host Shikha Jain, MD, about presentations on lymphoma at this year's ASCO meeting. 9:57 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20250531/study-reveals-shocking-rise-in-alcoholrelated-cancer-deaths https://www.healio.com/news/hematology-oncology/20250603/time-burden-people-with-cancer-face-often-vastly-underestimated https://www.healio.com/news/hematology-oncology/20250604/few-phase-3-oncology-trials-demonstrate-improvements-in-os-quality-of-life https://www.healio.com/news/hematology-oncology/20250522/glp1-receptor-agonists-confer-modest-protection-against-obesityrelated-cancers https://www.healio.com/news/hematology-oncology/podcasts/oncology-overdrive/episode-119 Exercise described as 'novel, first-in-class' colon cancer therapy Source: Booth CM, et al. Abstract LBA3510. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago. At-home intervention has potential to enhance cancer care delivery, outcomes Source: Nipp RD, et al. Abstract 11003. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago. Disclosures: Jani reports no relevant financial disclosures. Mavromatis reports no relevant financial disclosures. Sherry reports honoraria from Sermo.  Smith reports no relevant financial disclosures. Vogel reports a consulting/advisory role with Voluntis.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Academy of Neurology Annual Meeting. Mary A. O'Neal, MD, FAAN, and Ratna K. Bhavaraju-Sanka, MD, FAAN, discuss their efforts to address the lack of access to neurological care by partnering with primary care. :34 Merit E. Cudkowicz, MD, MSc, FAAN, speaks with Healio about being honored The American Academy of Neurology's Lifetime Achievement Award for her extensive work in ALS research. 2:50 Read the full coverage here: https://www.healio.com/news/neurology/20250417/partners-in-crime-neurologists-collaborate-with-pcps-to-improve-brain-health https://www.healio.com/news/neurology/20250407/merit-e-cudkowicz-md-msc-receives-lifetime-award-for-als-research-im-not-done-yet ACCORD-2: AXS-05 delays relapse time to Alzheimer's disease agitation Source: Grossberg G, et al. Efficacy and safety of AXS-05 in Alzheimer's disease agitation: Results from ACCORD-2, a phase 3 randomized withdrawal double-blind placebo-controlled study. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Risk for ARIA driven by patient genotype, presence of hemorrhage in early Alzheimer's Source: Biffi A, et al. ARIA insights from the donanemab trials: Amyloid-targeted therapy in early symptomatic Alzheimer's disease. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Microplastics in oceans may increase disability risk among coastal populations Source: Ganatra S, et al. Marine microplastics levels and the prevalence of neurologic disability. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Nightmares may increase risk for early death Source: Otaiku A, et al. Distressing dreams and risk of premature mortality: A population-based multicohort study. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego. Disclosures: Bhavaraju-Sanka reports serving as a consultant for Amgen and Argenx. Cudkowicz reports financial relationships with AB Science, AC Immune SA, Aclipse, Annals of Neurology, Biogen, Coya Therapeutics, Cytokinetics, Eli Lilly, Immunity Pharma, InFlectis, Locust Walk, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Pasithea Therapeutics, Pontifax, Praxis Precision Medicine, Transposon, QurAlis, Regeneron, VectorY. She also reports receiving publishing royalties from a publication relating to health care. Her institution(s) received support from ALS Finding a Cure, ALS ONE, Biohaven, Calico, Clene Nanomedicine, Denali, ITB, Johnson & Johnson, the National Institute of Neurological Disorders and Stroke, PharmAust, Prilenia, Seelos, UCB/RA and Woolsley. O'Neal reports serving as a consultant and excerpt witness for Circo; being an employee of Best Doctors; and receiving publishing royalties from a health care-related publication.

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition with a focus on leukemia, as well as Healio's top headlines from the meeting. Aaron T. Gerds, MD, MS, discusses how socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia. :24 Hua Zhang, MD, PhD, reviews findings of bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia. 6:29 Moath Albliwi, MD, discusses the results of a study he co-presented examining treatment of elderly patients with acute myeloid leukemia. 00:00 Alexey Danilov, MD, PhD, reviews the efficacy of epcoritamab among heavily pretreated patients with advanced chronic lymphocytic leukemia. 00:00 Lee Greenberger, PhD, discusses results of the AMPLIFY study. 16:30 Read the full coverage here: Socioeconomic factors a barrier to HSCT for people with acute myeloid leukemia Bicistronic CAR-T effective for children with relapsed B-ALL VIDEO: Study probes treatment of elderly patients with acute myeloid leukemia First-line regimen improves PFS in chronic lymphocytic leukemia Epcoritamab exhibits 'very encouraging' efficacy in heavily pretreated CLL Addition of blinatumomab to chemotherapy improves outcomes for children with B-cell ALL Disclosures: Albliwi reports no relevant financial disclosures. Danilov reports research funding from and/or consulting roles with AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Genmab, Incyte, Janssen and other companies. Please see the abstract for all other researchers' relevant financial disclosures. Gerds reports consulting roles with AbbVie, Bristol Myers Squibb, Disc Medicine, GSK, PharmaEssentia and Rain Oncology. Please see the abstract for all other researchers' relevant financial disclosures. Greenberger reports no relevant financial disclosures. Rau reports consulting/advisory roles with and/or honoraria from Jazz Pharmaceuticals and Servier. She also reports her spouse is employed by AbbVie. Please see the abstract for all other researchers' relevant financial disclosures. Zhang reports no relevant financial disclosures.